Press Releases

InVivo Therapeutics Announces University of Kansas Medical Center as New Site for Neuro-Spinal Scaffold Clinical Trial

Published: March 30, 2015

CAMBRIDGE, Mass. (March 30, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the University of Kansas Medical Center in Kansas City, KS has been added as a clinical site in the company’s ongoing Investigational Device Exemption (IDE) pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Paul Arnold, MD, Professor of Neurosurgery and Vice Chair of Research, has been named Principal Investigator at the site. “We look forward to participating in this exciting pilot study of an innovative device that is targeted at addressing the huge unmet medical need in the treatment of acute […]

View Article
InVivo Therapeutics Exhibiting at 66th Southern Neurosurgical Society Annual Meeting

Published: March 27, 2015

CAMBRIDGE, Mass. (March 27, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the company is exhibiting at the 66th Southern Neurosurgical Society (SNS) Annual Meeting being held in Naples, Florida on March 25-28, 2015. Tom Ulich, MD, InVivo’s Chief Scientific Officer, and Lorianne Masuoka, MD, InVivo’s Chief Medical Officer, are presenting intraoperative videos from the company’s ongoing Investigational Device Exemption (IDE) pilot study, which has enrolled two subjects thus far.  The videos provide an update to the neurosurgical community on the company’s investigational Neuro-Spinal Scaffold novel implantation techniques, which until InVivo’s pilot study, had never been performed in patients with […]

View Article
InVivo Therapeutics Announces Reopening of Enrollment for Subjects Three through Five for Anticipated Completion of Ongoing Pilot Trial

Published: March 26, 2015

CAMBRIDGE, Mass. (March 26, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the reopening of subject enrollment for the company’s ongoing Investigational Device Exemption (IDE) pilot study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. Barring significant safety issues, the final three subjects of this pilot trial will be enrolled concurrently and without mandatory safety hold between enrollment of each subject. To date, there have been no reported serious safety events related to the Neuro-Spinal Scaffold or the procedure to implant the Neuro-Spinal Scaffold with the study’s first and second subjects, and InVivo has been approved […]

View Article
InVivo Therapeutics Announces Keck Hospital of University of Southern California as New Site for Neuro-Spinal Scaffold Clinical Trial

Published: March 25, 2015

CAMBRIDGE, Mass. (March 25, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Keck Hospital of University of Southern California (USC) in Los Angeles, CA has been added as a clinical site in the company’s ongoing Investigational Device Exemption (IDE) pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). The Keck Hospital of USC is a 401-bed acute care hospital for the Keck Medical Center of USC, a system that comprises more than 500 faculty physicians. Patrick Hsieh, MD, Director of Neurosurgery Spine Program and Associate Professor of Neurological Surgery, has been named Principal […]

View Article
InVivo Therapeutics Announces Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ

Published: March 24, 2015

CAMBRIDGE, Mass. (Mar 24, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that its Board of Directors has approved a 1-for-4 reverse stock split of its issued and outstanding common stock in preparation for its planned uplisting to the NASDAQ Capital Market. The company anticipates the reverse stock split to become effective and its common stock to begin trading on a post-split basis at the open of trading on April 8, 2015, contingent upon approval from the Financial Industry Regulatory Authority (FINRA). “The execution of this reverse split represents an important step in achieving an essential corporate objective – […]

View Article
InVivo Therapeutics Reports 2014 Year End Financial Results and Business Update

Published: March 11, 2015

CAMBRIDGE, Mass. (March 11, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2014.

Mark Perrin, InVivo’s CEO and Chairman, said, “2014 was a momentous year for InVivo in every sense of the word. It’s gratifying to look back on how much we accomplished last year and exciting to see the trajectory the company is following. We are in a much better position to execute on our corporate goals than we were only 15 months ago and are significantly closer to achieving our mission: to redefine the life of the spinal cord injury patient. I’m pleased with how we’ve advanced as a company and am very much looking forward to a fruitful 2015.” […]

View Article
InVivo Therapeutics Announces Froedtert & the Medical College of Wisconsin as New Clinical Trial Site for Neuro-Spinal Scaffold

Published: February 23, 2015

CAMBRIDGE, Mass. (Feb 23, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Froedtert & the Medical College of Wisconsin (MCW) Froedtert Hospital in Milwaukee, WI has been added as a clinical site in the company’s ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Froedtert Hospital houses the only adult Level 1 trauma center in eastern Wisconsin and receives referred spinal cord injury patients from Wisconsin, northern Illinois, and northern Michigan. Shekar Kurpad, MD, PhD, professor of neurosurgery at MCW and director of the Spinal Cord Injury Center and Spine Surgery Fellowship at Froedtert Hospital, has been named Principal Investigator at the site […]

View Article
InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer

Published: February 9, 2015

CAMBRIDGE, Mass.(BUSINESS WIRE) InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Lorianne Masuoka, MD, as Chief Medical Officer (CMO), effective March 2, 2015. She will be taking over for the interim CMO, Lou Vaickus, MD, who is also Founder & President of akta Pharmaceutical Development LLC, a life sciences consulting company. […]

View Article
InVivo Therapeutics Announces CEO Mark Perrin Named Chairman of the Board

Published: February 5, 2015

CAMBRIDGE, Mass. (Feb 5, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Mark D. Perrin as Chairman of InVivo’s Board of Directors, effective immediately. Perrin has served as a Board member and Chief Executive Officer of the company since January 2014. John A. McCarthy, Jr., current non-executive Chairman of the Board […]

View Article
InVivo Therapeutics Announces $12 Million Registered Direct Offering

Published: January 29, 2015

InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has received commitments from two dedicated health care funds to purchase an aggregate of $12 million of the Company’s common stock in a registered direct offering. The Company entered into a definitive purchase agreement with these investors pursuant to which the Company agreed to sell an aggregate of 8,000,000 shares of its common stock at a per share price of $1.50. The closing of the offering is expected to take place on or about January 29, 2015, subject to the satisfaction of customary closing conditions […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.